ATE542829T1 - Impfstoff - Google Patents

Impfstoff

Info

Publication number
ATE542829T1
ATE542829T1 AT02751380T AT02751380T ATE542829T1 AT E542829 T1 ATE542829 T1 AT E542829T1 AT 02751380 T AT02751380 T AT 02751380T AT 02751380 T AT02751380 T AT 02751380T AT E542829 T1 ATE542829 T1 AT E542829T1
Authority
AT
Austria
Prior art keywords
antigens
antigenic polypeptides
vaccine
vaccines
expressed
Prior art date
Application number
AT02751380T
Other languages
English (en)
Inventor
S Foster
James Mond
S Clarke
P Mcdowell
K Brummel
Original Assignee
Univ Sheffield
Biosynexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0118825A external-priority patent/GB0118825D0/en
Priority claimed from GB0200349A external-priority patent/GB0200349D0/en
Application filed by Univ Sheffield, Biosynexus Inc filed Critical Univ Sheffield
Application granted granted Critical
Publication of ATE542829T1 publication Critical patent/ATE542829T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02751380T 2001-08-02 2002-08-02 Impfstoff ATE542829T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0118825A GB0118825D0 (en) 2001-08-02 2001-08-02 Antigenic polypeptides
GB0200349A GB0200349D0 (en) 2002-01-09 2002-01-09 Antigenic polypeptides
PCT/GB2002/003606 WO2003011899A2 (en) 2001-08-02 2002-08-02 Antigenic polypeptides

Publications (1)

Publication Number Publication Date
ATE542829T1 true ATE542829T1 (de) 2012-02-15

Family

ID=26246393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751380T ATE542829T1 (de) 2001-08-02 2002-08-02 Impfstoff

Country Status (7)

Country Link
US (2) US7410647B2 (de)
EP (1) EP1412379B1 (de)
JP (1) JP4404627B2 (de)
AT (1) ATE542829T1 (de)
AU (1) AU2002355677A1 (de)
CA (2) CA2808598A1 (de)
WO (1) WO2003011899A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
CA2520868A1 (en) * 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
US20060188515A1 (en) * 2003-07-24 2006-08-24 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphylococcus aureus
CA2555342A1 (en) * 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
FR2871237B1 (fr) * 2004-06-08 2011-03-11 Abag Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections staphylococciques sur protheses articulaires et autres materiels etrangers implantes
FR2871159A1 (fr) * 2004-06-08 2005-12-09 Abag Sa Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a staphylocoques a coagulase negative
ES2730275T3 (es) 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
EP2213298A3 (de) 2004-10-21 2011-07-20 Wyeth LLC Imunogene Zusammensetzungen von Staphylococcus Epidermidis Polypeptide und Polynucleotide Antigenen
CA2581746A1 (en) * 2004-10-25 2006-06-08 The University Of Western Ontario Staphylococcus aureus isd protein-based anti-infectives
KR101541383B1 (ko) 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
GB0610776D0 (en) * 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
ATE537839T1 (de) * 2007-05-04 2012-01-15 Martin Kroenke Impfstoff zum schutz gegen staphylococcus aureus auf der basis zellwandassoziierter proteine
CA2697538C (en) 2007-08-31 2019-02-12 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
PL2268618T3 (pl) 2008-03-03 2015-11-30 Novartis Ag Związki i kompozycje jako modulatory aktywności receptorów TLR
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
US8101190B2 (en) * 2009-03-03 2012-01-24 Ingen Biosciences Method for diagnosing staphylococcal infections
SMT202000246T1 (it) 2009-04-03 2020-07-08 Univ Chicago Composizioni e metodi relativi a varianti della proteina a (spa)
CN102762226A (zh) 2009-06-10 2012-10-31 诺华有限公司 含苯并萘啶的疫苗
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
JP5848748B2 (ja) 2010-03-23 2016-01-27 アイアールエム・リミテッド・ライアビリティ・カンパニーIrm,Llc 感染症、炎症、呼吸器疾患などの処置に使用するtlr2アゴニストとしての化合物(システインベースのリポペプチド)および組成物
BR112013000097B1 (pt) 2010-07-02 2022-02-01 The University Of Chicago Polipeptídeo imunogênico isolado, composição imunogênica e seu uso
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US9527892B2 (en) 2011-10-31 2016-12-27 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2451 protein
US20140377260A1 (en) * 2011-10-31 2014-12-25 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2074 protein
EP2844275B1 (de) * 2012-04-26 2020-05-13 University of Chicago Staphylokokken-coagulase-antigene und verfahren zu deren verwendung
WO2014011645A1 (en) 2012-07-10 2014-01-16 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2493 protein
US9777076B2 (en) 2012-07-16 2017-10-03 Pfizer Inc. Saccharides and uses thereof
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
IL276608B2 (en) 2018-02-12 2024-04-01 Inimmune Corp Toll-like receptor ligands
JP2023547676A (ja) 2020-11-04 2023-11-13 エリゴ・バイオサイエンス DNAペイロードをアクネ菌集団へとin situ送達するためのファージ由来粒子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
GB8905857D0 (en) * 1989-03-14 1989-04-26 Hoffmann La Roche Plasmodium merozoite rhoptries antigen
US6086896A (en) * 1990-07-16 2000-07-11 Imclone Systems Incorporated Antigenic iron repressible protein from N. meningitidis related to the hemolysin family of toxins
US6008341A (en) * 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
GB9806762D0 (en) 1998-03-31 1998-05-27 Neutec Pharma Plc Treatment and diagnosis of staphylococcal infections
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP2320233A1 (de) * 2001-06-15 2011-05-11 Inhibitex, Inc. Kreuzreaktive monoklonale und polyklonale Antikörper, die Oberflächenprotein aus Koagulasenegativen Staphylococci und Staphylococcus aureus erkennen

Also Published As

Publication number Publication date
AU2002355677A1 (en) 2003-02-17
EP1412379A2 (de) 2004-04-28
US20090269349A1 (en) 2009-10-29
WO2003011899A3 (en) 2004-02-26
US20050256299A1 (en) 2005-11-17
CA2808598A1 (en) 2003-02-13
CA2453937C (en) 2013-05-14
EP1412379B1 (de) 2012-01-25
CA2453937A1 (en) 2003-02-13
JP4404627B2 (ja) 2010-01-27
JP2004536885A (ja) 2004-12-09
WO2003011899A2 (en) 2003-02-13
US7410647B2 (en) 2008-08-12

Similar Documents

Publication Publication Date Title
ATE542829T1 (de) Impfstoff
NO20025838L (no) Antigeniske polypeptider
NO20033364L (no) Fremgangsmåte for identifikasjon, isolasjon og produksjon av antigener tilet spesifikt patogen
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
BR0206565A (pt) Arranjo de antìgeno molecular
IS7133A (is) Afleiða beta-amyloid - T-frumu-mótefnavísisbóluefni
ATE384793T1 (de) Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen
AP2003002734A0 (en) Purification of HBV antigens for use in vaccines.
DK1259259T3 (da) Mucosal adjuvansformulering
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
CY1111521T1 (el) Λοιμογονος συστηματικος καλυκοϊος αιλουροειδων
IL144265A0 (en) Use of antibodies for the vaccination against cancer
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
GB0409559D0 (en) Polypeptide
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
WO2004073604A3 (en) Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity
ECSP034474A (es) Nuevo tratamiento
AU2003294192A8 (en) Inclusion bodies as antigens for the oral vaccination of animals